STX-0640

About Solu Therapeutics

Solu Therapeutics is a private, clinical-stage biotech developing a groundbreaking platform that conjugates bifunctional small molecules to antibodies, creating novel drug classes like CyTACs and TicTACs. This approach allows targeting of previously inaccessible cell surface proteins, such as GPCRs, with enhanced specificity and pharmacokinetics. The company's lead asset, STX-0712, is in Phase 1 for chronic myelomonocytic leukemia (CMML), with a pipeline spanning oncology, immunology, and pain. Backed by experienced leadership and venture capital, Solu leverages an exclusive license from GSK and aims to rapidly advance programs from concept to clinic.

Therapeutic Areas